entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 18:16:16 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.

The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Nonprofit, backed by Microsoft, to certify AI tools in health care

leisure time

WSS

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Pig kidney works a record two months in donated body

Hospitals consider fixing cancer drug shortages on their own

Allen Institute goes after foundational questions, CEO Costa says

focus

entertainment

focus

As demand for Covid shots wanes, Moderna seeks its next success

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

State Dept. review finds Biden bears some blame for Afghanistan failures

Does Paxlovid work in people vaccinated against Covid

Medical leaders decry Supreme Court decision on affirmative action

New Covid vaccine is recommended for everyone 6 months or older

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stories you might have missed in 2023: health, science, medicine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Male doctors called my cancer incurable. A female doctor showed it wasn't

hotspot

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Hospital chaplains balance Covid safety with patients’ spiritual needs

Popular nasal decongestant doesn't actually relieve congestion

At JPM 2024, hospital systems pitch financial strength to investors

IRA could hurt research into orphan drugs for rare diseases

Life science postdocs should get big pay hike, NIH panel says

focus

explore

leisure time

explore